Clin Osteol 2013; 18(3): 87-90

Giant-cell epulis: immunohistochemical analysis of MGMT, p53, OPN and MMP-1Original contributions

Y. Kuzenko, A. Romanyuk

Object: The object of this study was to analyze the expression of MGMT, p53, OPN and MMP-1 in giant-cell epulis.

Methods: 10 giant-cell epulis were evaluated for expression of MGMT, p53, OPN and MMP-1 by immunohistochemistry.

Results: Strong giant-cell positivity for MGMT was observed in 96.9 ± 0.5 % (P < 0.05). Strong mesenchymal immunoreactivity for MMP-1 was figured in giant-cell, 75.9 ± 1.33 % and in the stroma 54.12 ± 1.36 % (P < 0.05). Immunoreactivity for OPN was fixed in the giant-cell of epulis 15.77 ± 1.8%., positivity for p53 was found in 5.67 ± 0.32 % of giant-cell contrast and in the stroma 0 %.

Conclusion: MGMT, p53 and OPN may play important roles in the biology of giant-cell epulis. Furthermore, theMMP-1 of these pro­ teases at higher levels in giant-cell epulis may help to explain invasion in bone matrix.

Keywords: MGMT, p53, OPN and MMP-1, immunohistochemistry, oral giant-cell epulis

Published: December 11, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kuzenko Y, Romanyuk A. Giant-cell epulis: immunohistochemical analysis of MGMT, p53, OPN and MMP-1. Osteologický bulletin. 2013;18(3):87-90.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kramer IRH, Pindborg JJ, Shea M. Hist ed. Berlin, Springer-Verlag 1992; p 118.
    2. Adornato MC, Paticoff KA Intralesional corticosteroid injection for treatme central giant-cell granuloma. J Am Dent Assoc 2001;132:186-190. Go to original source...
    3. Neville BW, Damm DD, Allen CM, Bouquot JE. Soft Tissue Tumors. In: Oral and Maxillofacial Pathology. 3rd ed. St. Louis: Saunders 2009; pp.507-563. Go to original source...
    4. Willing M, Engels C, Jesse N, Werner M, Delling G, Kaiser E. The nature o ant cell tumor of bone. J Cancer Res ClinOncol 2001;127:467-474. Go to original source...
    5. Falaschini S, Ciavarella D, Mazzanti R, Di Cosola M, Turco M, Escudero N, Bascones A, Lo Muzio L. Peripheral giant cell granuloma: immunohistochemical analysis of different ma gia. 2007;23(4):189-196.
    6. Palacios 2000;79:688.
    7. Hoeijmakers JH. 2001; 411:366-374.
    8. Giaginis C, Michailidi C, Stolakis V, Alexandrou P, Tsourouflis G, Klijanienk Delladetsima I, Theocharis S. Expression of DNA repair proteins MSH2, MLH1 and MGMT in human benign and malignant thyroid lesions: An immunohisto­ chemical study. Med Sci Monit 2011;17(3):81-90. Go to original source...
    9. Ryan KM, Phillips AC, Karen H. Regulation and function of the p53 tumor supp­ ressor protein. Vousden Current Opinion in Cell Biology 2001;13:332-337. Go to original source...
    10. Merry K, Dodds R, Littlewood A, Gowen M. Expression of Osteopontin mRNA by osteoclasts and osteoblasts in modelling adult human bone. J Cell Sci 1993; 104(4):1013-1020. Go to original source...
    11. Kelly L, Hudkins, Quoc CLE, Segerer S, Johnson RJ, Davis CL, Giachelli CM, Alpers ChE. Osteopontin expression in human cyclosporine toxicity. Kidney International 2001;60:635-640. Go to original source...
    12. Sutinen M, Kainulainen T, Hurskainen T, Vesterlund E, Alexander JP, Overall CM, Sorsa T, Salo T. Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squam cell carcinoma and lymph node metastasis. Br J Cancer 1998;77(12):2239-2245. Go to original source...
    13. Ko LJ. Prives C P53: puzzle and paradigm. Genes Dev 1996;10:1054-1072. Go to original source...
    14. Sawhney M, Rohatgi N, Kaur J et al. MGMT expression in oral precancerous and cancerous lesions: correlation with progression, nodal metastasis and poor pro­ gnosis. Oral Oncol 2007;43:515-522. Go to original source...
    15. Delaisse JM, Engsig MT, Everts V, Ovejero MC, Ferreras M, Lund L et al. Proteinases in bone resorption: obvious and less obvious roles. Clin Chim Acta 2000;291:223-234. Go to original source...
    16. Ala-Aho R, Kahari VM. Collagenases in cancer. Biochimie 2005;87:273-286. Go to original source...
    17. Henriques CG, de Matos FR, Galvao HC, de A Freitas R. Immunohistochemical expression of MMP-9 and VEGF in squamous cell carcinoma of the tongue. Aguida Journal of Oral Science 2012;54(1):105-111. Go to original source...
    18. Packer L, Pavey S, Parker A et al. Osteopontin is a downstream effector PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN. Carcinogenesis 2006;27:1778-1786. Go to original source...
    19. Hudkins KL, Giachelli CM, Cui Y et al. Osteopontin expression characterization of small proteoglycans I and II, bone sial ney. Kidney International 2000;60:635-640. Go to original source...
    20. Le QT, Sutphin PD, Raychaudhuri S et al. Identification of osteopontin as a p gnostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 2003;9:59-67.
    21. Kelly SL, Sullards MC, Murphy RC et al. Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses. Cell 2012; 151:138-152. Go to original source...
    22. Cappia S, Righi L, Mirabelli D et al. Prognostic role of ost malignant pleural mesothelioma. Am J Clin Pathol 2008;130:58-64. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.